The advent of new ad-unit lengths is bringing drugmakers much-needed relief from the high cost of advertising on television.
Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.
Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.
JMI Health is launching PharmQD, which aims to be something like a cross between LinkedIn and Facebook for pharmacy students, hospital and retail pharmacists, said JMI SVP, eproducts Tina Pang Mayer (pictured).
Physicians say patient compliance is getting worse, and they're hearing more requests for generic or OTC alternatives to prescribed medications as the economic malaise takes its toll, according to a PriMed survey.
The Coalition for Healthcare Communication said it doesn't oppose ACCME's proposal to set up an independent entity for disbursal of CME funding - provided that it's not the only game in town and CME providers don't have to pay for it.
A pair of American Medical Association committee reports urges that industry-funded CME be put on a tighter leash, but they're a far cry from the ban on commercial support called for by the AMA's Council on Ethical and Judicial Affairs a year ago.
Marketers anticipate substantial cuts in DTC spend in 2009, according to a Cegedim Dendrite survey in which 58% of respondents said they'd cut consumer ad spend this year. Last year 28% said they'd cut back on consumer advertising.
Pfizer hired onetime Gore advisor turned healthcare think tanker Gregory Simon to head its global policy efforts as the industry gears up for a health reform fight in Washington.
WebMD hopes to extend its professional network reach with the launch of a Medscape iPhone application. The app will become available during the last week of May, or in early June, according to a WebMD spokesperson.
Johnson & Johnson's McNeil Pediatrics launched a second ADHD-focused Facebook page on April 22, this time targeting adults in the US with the disorder.
It seems corporate reputation is countercyclical for pharmas, as well. The drug industry was the only sector to see appreciable gains in public perception from 2007 to 2008, according to Harris Interactive, posting its highest rating in five years as financial services firms and automakers displaced pharmas in the dregs of public esteem alongside tobacco.
Physicians and medical institutions should shun gifts, reps, samples and ghostwriting, said the Institute of Medicine's conflict of interest committee in its full recommendations.
Sixty-seven percent of physicians had a positive attitude toward electronic promotional activities, up from 62% a year ago, according to an SDI study.
Consumers worldwide overwhelmingly prefer medicines that have been around a long time to the latest treatments, and over half prefer generics to branded drugs given the choice, according to a DDB Health survey.
GlaxoSmithKline is buying dermatology specialist Steifel for $3.6 billion.
The Accreditation Council for Continuing Medical Education said that for the time being, it won't ban commercial support of CME.
TV ads for prescription drugs loosened up a bit in 2008 and exercised greater creativity despite intense scrutiny, The Nielsen Company found in a review of advertising recall rates for 2008.
Stanford University's school of medicine will publicly disclose pharma industry payments to its faculty and physicians, whenever those payments exceed $5,000 per year.
The Journal of the American Medical Association is calling for professional medical associations to sever all ties with the drug industry--with exception to journal advertising and exhibit hall fees, of course.
The American Psychiatric Association (APA) will put an end to industry-sponsored continuing medical education (CME) and meals served during its annual meetings, the association said Wednesday.
GlaxoSmithKline said it will broaden its transparency policies to include greater disclosure of its clinical research and the physicians the company works with on clinical trials.
Job security for pharma sales reps is looking bleak, going by the results of a ZS Associates study. The survey found that the number of US reps has plummeted 10% since 2007 to 92,000, and the management consultancy projects a further decline, to 75,000 by 2012.
Iowa's state Senate passed a healthcare bill containing some of the toughest restrictions on drug company contacts with physicians yet.
IMS said US prescription drug sales grew 1.3% in 2008 to $291 billion amid increased use of generics, lower sales of new products and slackening consumer demand resulting from the economic downturn.
In just the first three months of 2009, several of the largest companies in the industry announced mergers that will change the face of an industry dogged by sluggish pipelines.
Pharmaceutical industry ad spend fell 18.4% in 2008 to $4.3 billion in the US, according to The Nielsen Company. J&J, the sole drug company among the nation's top 10 advertisers, spent $1.2 billion on advertising -- a drop of 5.4% from 2007 spend.
Roche will buy all remaining shares of Genentech at $95 dollars apiece, or $46.8 billion total, the companies announced in a joint statement. Prior to the deal, Roche held 56% of the company's shares.
Massachusetts passed regulation governing drug and device company sales and marketing that the state's deputy counsel boasted is "the most stringent of the existing state laws" and "sets PhRMA and AdvaMed codes as the floor."
Recession got you down? Having second thoughts about filling that prescription? How about some help with your co-pay? That's the tack Bristol-Myers Squibb is taking with its Orencia Promise program.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.